Eli Lilly and Co (MIL:1LLY) Stock Price, Trades & News

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Financial Strength

6/10

Name	Current	Vs Industry
Cash-To-Debt	0.12
Equity-to-Asset	0.27
Debt-to-Equity	1.39
Debt-to-EBITDA	1.15
Interest Coverage	50.14
Piotroski F-Score	8/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	9.51	Distress Grey Safe
Beneish M-Score	-1.67	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	31.9
	3-Year EBITDA Growth Rate	54.4
	3-Year EPS without NRI Growth Rate	45
	3-Year FCF Growth Rate	9.3
	3-Year Book Growth Rate	38.3
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	28.62
	Future 3-5Y Total Revenue Growth Rate Estimate	19.27

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	39.22
	9-Day RSI	51.58
	14-Day RSI	56.88
	3-1 Month Momentum %	25.34
	6-1 Month Momentum %	8.16
	12-1 Month Momentum %	47.53

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.5
	Quick Ratio	1.1
	Cash Ratio	0.14
	Days Inventory	357.67
	Days Sales Outstanding	79.32
	Days Payable	130.57

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	0.54
	Dividend Payout Ratio	0.21
	3-Year Dividend Growth Rate	15.2
	Forward Dividend Yield %	0.58
	5-Year Yield-on-Cost %	1.1
	3-Year Average Share Buyback Ratio	2
	Shareholder Yield %	0.19

Profitability Rank

10/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	82.83
	Operating Margin %	47.3
	Net Margin %	34.99
	EBITDA Margin %	52.34
	FCF Margin %	14.32
	OCF Margin %	28.3
	ROE %	109.36
	ROA %	23.65
	ROIC %	36.48
	3-Year ROIIC %	35.59
	ROC (Joel Greenblatt) %	105.61
	ROCE %	50.64
	Years of Profitability over Past 10-Year	9
	Moat Score	8
	Tariff Resilience Score	8

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	42.22
	Forward PE Ratio	33.27
	PE Ratio without NRI	40.38
	Shiller PE Ratio	129.56
	Price-to-Owner-Earnings	84.31
	PEG Ratio	1.32
	PS Ratio	14.77
	PB Ratio	34.04
	Price-to-Tangible-Book	60.03
	Price-to-Free-Cash-Flow	102.96
	Price-to-Operating-Cash-Flow	52.12
	EV-to-EBIT	30.69
	EV-to-Forward-EBIT	30.97
	EV-to-EBITDA	29.03
	EV-to-Forward-EBITDA	28.82
	EV-to-Revenue	15.2
	EV-to-Forward-Revenue	12.76
	EV-to-FCF	105.9
	Price-to-GF-Value	0.84
	Price-to-Projected-FCF	14.45
	Price-to-DCF (Earnings Based)	1.58
	Price-to-DCF (FCF Based)	6.85
	Price-to-Median-PS-Value	1.9
	Price-to-Peter-Lynch-Fair-Value	1.62
	Price-to-Graham-Number	10.38
	Earnings Yield (Greenblatt) %	3.26
	FCF Yield %	0.98
	Forward Rate of Return (Yacktman) %	20.28

Financials (Next Earnings Date:2026-08-05)

Annual Quarterly TTM

MIL:1LLY's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Eli Lilly and Co Executives

Details

GF Value™: €1231.62

MIL:1LLY

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with 1LLY. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	62,085.911
	EPS (TTM) (€)	24.2
	Beta	-
	3-Year Sharpe Ratio	-
	3-Year Sortino Ratio	-
	Volatility %	39.58
	14-Day RSI	56.88
	14-Day ATR (€)	31.632004
	20-Day SMA (€)	1018.73
	12-1 Month Momentum %	47.53
	52-Week Range (€)	535.2 - 1090.6
	Shares Outstanding (Mil)	891.74

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	8
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Eli Lilly and Co Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Eli Lilly and Co Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-10-29 10:00	In 110 days
Third quarter earnings results for 2026	2026-10-29	In 109 days
USD 1.730000 Cash Dividend	2026-08-14	In 33 days
Second quarter earnings conference call for 2026	2026-08-05 10:00	In 25 days
Second quarter earnings results for 2026	2026-08-05	In 24 days
Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-09 15:20	1,006.60 (-2.91%)
Investor event	2026-06-06 18:00	1,007.60 (+3.87%)
USD 1.730000 Cash Dividend	2026-05-15	858.50 (-0.90%)
General meeting for 2026	2026-05-04 09:30	786.50 (+7.58%)
First quarter earnings conference call for 2026	2026-04-30 10:00	733.10 (-1.99%)

Show

Entries

Eli Lilly and Co Frequently Asked Questions

What is Eli Lilly and Co(MIL:1LLY)'s stock price today?

The current price of MIL:1LLY is €1037.40. The 52 week high of MIL:1LLY is €1090.60 and 52 week low is €535.20.

When is next earnings date of Eli Lilly and Co(MIL:1LLY)?

The next earnings date of Eli Lilly and Co(MIL:1LLY) is 2026-08-05.

Does Eli Lilly and Co(MIL:1LLY) pay dividends? If so, how much?

The Dividend Yield % of Eli Lilly and Co(MIL:1LLY) is 0.54% (As of Today), Highest Dividend Payout Ratio of Eli Lilly and Co(MIL:1LLY) was 0.72. The lowest was 0.21. And the median was 0.44. The Forward Dividend Yield % of Eli Lilly and Co(MIL:1LLY) is 0.58%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
	/C O R R E C T I O N -- Eli Lilly and Company/	2026-07-09
	Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment	2026-07-09
	Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy	2026-06-26
	What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management	2026-06-25
	Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders	2026-06-24
	Lilly declares third-quarter 2026 dividend	2026-06-22
	Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL	2026-06-14
	Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting	2026-06-13
	Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable	2026-06-10
	FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis	2026-06-09

10/Page

Articles on Eli Lilly and Co

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.